A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

Pfizer faces mounting challenges including a failed phase 3 clinical trial for cancer drug sigvotatug vedotin and the departure of CFO Dave Denton. Despite these setbacks and the $43 billion Seagen acquisition, the article argues the stock remains attractive due to strong pipeline candidates like MET-097i in weight loss, successful products like Padcev and Abrysvo, and a solid 7.3% dividend yield.